<p>RNS 編號：8655M 摩根大通 2025 年 12 月 24 日</p>
<p><strong>表格 38.5(b)</strong></p>
<p><strong>愛爾蘭收購委員會</strong></p>
<p><strong>根據 1997 年愛爾蘭收購委員會法第 38.5(b) 條款的披露，收購規則，2013</strong></p>
<p><strong>與沒有被認可中介身份的關聯豁免主要交易者的交易，或與被認可中介身份但不以客户服務身份進行交易的交易</strong></p>
<p><strong>1. 關鍵信息</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>豁免主要交易者名稱</td>
<td>摩根大通</td>
</tr>
<tr>
<td>交易公司</td>
<td>Avadel Pharmaceuticals PLC</td>
</tr>
<tr>
<td>涉及的相關證券類別（注 1）</td>
<td>0.01 美元普通股</td>
</tr>
<tr>
<td>交易日期</td>
<td>2025 年 12 月 23 日</td>
</tr>
</tbody>
</table>
<p><strong>2. 利益和空頭頭寸</strong></p>
<p><strong>(a) 在所交易的相關證券類別中的利益和空頭頭寸（交易後）(注 2)</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>多頭</td>
<td>空頭</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>數量</td>
<td>(%)</td>
<td>數量</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) 相關證券</td>
<td>943,558</td>
<td>(0.96)</td>
<td>486,565</td>
<td>(0.49)</td>
</tr>
<tr>
<td>(2) 衍生品（非期權）</td>
<td>39,256</td>
<td>(0.04)</td>
<td>63,843</td>
<td>(0.06)</td>
</tr>
<tr>
<td>(3) 購買/出售的期權和協議</td>
<td>0</td>
<td>(0.00)</td>
<td>0</td>
<td>(0.00)</td>
</tr>
<tr>
<td>總計</td>
<td>982,814</td>
<td>(1.00)</td>
<td>550,408</td>
<td>(0.56)</td>
</tr>
</tbody>
</table>
<p><strong>(b) 在公司相關證券中的利益和空頭頭寸，除了所交易的類別（注 2）</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相關證券類別：</td>
<td>多頭</td>
<td>空頭</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>數量</td>
<td>(%)</td>
<td>數量</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) 相關證券</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 衍生品（非期權）</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 購買/出售的期權和協議</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>總計</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>3. 交易（注 3）</p>
<p><strong>(a) 購買和銷售</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>購買/銷售</td>
<td>相關證券數量</td>
<td>每單位價格（注 4）</td>
</tr>
<tr>
<td>購買</td>
<td>5,451</td>
<td>21.6050 美元</td>
</tr>
<tr>
<td>購買</td>
<td>300</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>購買</td>
<td>1,162</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>購買</td>
<td>400</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>購買</td>
<td>1,232</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>購買</td>
<td>1,493</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>購買</td>
<td>381</td>
<td>21.6250 美元</td>
</tr>
<tr>
<td>購買</td>
<td>21</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>購買</td>
<td>100</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>購買</td>
<td>75</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>購買</td>
<td>188</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>購買</td>
<td>100</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>銷售（新貸款）</td>
<td>1,300</td>
<td>不適用</td>
</tr>
<tr>
<td>購買（貸款全額歸還）</td>
<td>1,300</td>
<td>不適用</td>
</tr>
<tr>
<td>銷售（新貸款）</td>
<td>1,300</td>
<td>不適用</td>
</tr>
<tr>
<td>購買（貸款部分歸還）</td>
<td>659</td>
<td>不適用</td>
</tr>
<tr>
<td>銷售（新貸款）</td>
<td>690</td>
<td>不適用</td>
</tr>
<tr>
<td>購買（貸款全額歸還）</td>
<td>690</td>
<td>不適用</td>
</tr>
<tr>
<td>銷售（借入部分歸還）</td>
<td>194,400</td>
<td>不適用</td>
</tr>
</tbody>
</table>
<p><strong>(b) 衍生品交易（非期權交易）</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>產品名稱，例如 CFD</td>
<td>CFD</td>
</tr>
<tr>
<td>交易性質（注 5）</td>
<td>減少多頭頭寸</td>
</tr>
<tr>
<td>相關證券數量（注 6）</td>
<td>10,903</td>
</tr>
<tr>
<td>每單位價格（注 4）</td>
<td>21.5893 美元</td>
</tr>
</tbody>
</table>
<p><strong>(c) 關於現有相關證券的期權交易</strong></p>
<p><strong>(i) 寫入、出售、購買或變更</strong></p>
<ul>
<li>產品名稱，例如看漲期權</li>
<li>寫入、出售、購買、變更等</li>
<li>與期權相關的證券數量（注 7）</li>
<li>行使價格</li>
<li>類型，例如美式、歐式等</li>
<li>到期日期</li>
<li>每單位支付/收到的期權費用（注 4）</li>
</ul>
<p><strong>(ii) 行使</strong></p>
<ul>
<li>產品名稱，例如看漲期權</li>
<li>證券數量</li>
<li>每單位行使價格（注 4）</li>
</ul>
<p><strong>(d) 其他交易（包括新證券的交易）（注 3）</strong></p>
<ul>
<li>交易性質（注 7）</li>
<li>詳情</li>
<li>每單位價格（如適用）（注 4）</li>
</ul>
<p><strong>4. 其他信息</strong></p>
<p><strong>與期權或衍生品相關的協議、安排或理解</strong></p>
<ul>
<li>任何披露人和其他人之間關於本表格中提到的任何期權下相關證券投票權的協議、安排或理解的完整細節，或關於本表格中提到的任何衍生品的相關證券的投票權或未來收購或處置的協議。如果沒有，應予以説明。</li>
<li>無</li>
</ul>
<p>是否附有補充表格 8？（注 9）是</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 12 月 24 日</td>
</tr>
<tr>
<td>聯繫人姓名</td>
<td>Papa Lette 和 Andrzej Szyszka</td>
</tr>
<tr>
<td>電話號碼</td>
<td>+33(1) 4212 1459 / +48(22) 317 4817</td>
</tr>
<tr>
<td>與之相關的受要約方/要約方名稱</td>
<td>Avadel Pharmaceuticals PLC</td>
</tr>
<tr>
<td>關係性質（注 9）</td>
<td>受要約方顧問</td>
</tr>
</tbody>
</table>
<p><strong>補充表格 38.5(b)</strong></p>
<p><strong>愛爾蘭收購委員會</strong></p>
<p><strong>根據 1997 年愛爾蘭收購委員會法第 38.5(b) 條款的披露，收購規則，2013</strong></p>
<p><strong>開放頭寸的詳細信息</strong></p>
<p><strong>開放頭寸（注 1）</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>產品名稱，例如看漲期權</td>
<td>寫入或購買</td>
<td>與期權或衍生品相關的相關證券數量</td>
<td>行使價格（注 2）</td>
<td>類型，例如美式、歐式等</td>
<td>到期日期</td>
</tr>
<tr>
<td>互換</td>
<td>出售</td>
<td>84</td>
<td>0.0000</td>
<td>不適用</td>
<td>2026 年 3 月 13 日</td>
</tr>
<tr>
<td>互換</td>
<td>購買</td>
<td>33,762</td>
<td>0.0000</td>
<td>不適用</td>
<td>2026 年 1 月 20 日</td>
</tr>
</tbody>
</table>
<p>註釋</p>
<p>1. 如果存在開放的期權頭寸或開放的衍生品頭寸（除 CFD 外），應提供完整的細節。任何現有的購買或出售協議的完整細節也必須在本表格中提供。</p>
<p>2. 所有價格和其他貨幣金額必須註明貨幣。</p>
<p>有關披露要求的完整細節，請參見規則 8 和規則 38.5。如果有疑問，請諮詢委員會。</p>
<p>此信息由 RNS 提供，倫敦證券交易所的新聞服務。RNS 已獲得金融行為監管局的批准，作為英國的主要信息提供者。有關使用和分發此信息的條款和條件可能適用。如需更多信息，請聯繫 rns@lseg.com 或訪問 www.rns.com。</p>
<p>RNS 可能會使用您的 IP 地址來確認您是否遵守條款和條件，分析您與本次溝通中所包含信息的互動方式，並將此分析以匿名方式與他人分享，作為我們商業服務的一部分。有關 RNS 和倫敦證券交易所如何使用您提供的個人數據的更多信息，請參閲我們的隱私政策。END ITPUSVARVOUUUAA</p>

高盛

Avadel制藥

<p>高盛公司（Goldman Sachs & Co. LLC）根據 1997 年愛爾蘭收購委員會法第 38.5(b) 條款披露了與 Avadel 製藥（Avadel Pharmaceuticals plc）的交易情況。該披露包括對 0.01 美元普通股的權益和空頭頭寸、相關證券的買賣以及衍生品交易。該披露是愛爾蘭收購委員會的要求，附有補充表格。高盛擔任 Avadel 製藥的顧問</p>

<p>RNS Number : 8655M Goldman Sachs &amp; Co. LLC 24 December 2025</p>
<div class="lb-trans"><p>RNS 編號：8655M 摩根大通 2025 年 12 月 24 日</p>
</div><p><strong>FORM 38.5(b)</strong></p>
<div class="lb-trans"><p><strong>表格 38.5(b)</strong></p>
</div><p><strong>IRISH TAKEOVER PANEL</strong></p>
<div class="lb-trans"><p><strong>愛爾蘭收購委員會</strong></p>
</div><p><strong>DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013</strong></p>
<div class="lb-trans"><p><strong>根據 1997 年愛爾蘭收購委員會法第 38.5(b) 條款的披露，收購規則，2013</strong></p>
</div><p><strong>DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY</strong></p>
<div class="lb-trans"><p><strong>與沒有被認可中介身份的關聯豁免主要交易者的交易，或與被認可中介身份但不以客户服務身份進行交易的交易</strong></p>
</div><p><strong>1. KEY INFORMATION</strong></p>
<div class="lb-trans"><p><strong>1. 關鍵信息</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of exempt principal trader</td>
<td>GOLDMAN SACHS &amp; CO. LLC</td>
</tr>
<tr>
<td>Company dealt in</td>
<td>AVADEL PHARMACEUTICALS PLC</td>
</tr>
<tr>
<td>Class of relevant security to which the dealings being disclosed relate (Note1)</td>
<td>USD 0.01 ordinary shares</td>
</tr>
<tr>
<td>Date of dealing</td>
<td>23 December 2025</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>豁免主要交易者名稱</td>
<td>摩根大通</td>
</tr>
<tr>
<td>交易公司</td>
<td>Avadel Pharmaceuticals PLC</td>
</tr>
<tr>
<td>涉及的相關證券類別（注 1）</td>
<td>0.01 美元普通股</td>
</tr>
<tr>
<td>交易日期</td>
<td>2025 年 12 月 23 日</td>
</tr>
</tbody>
</table>
</div><p><strong>2. INTERESTS AND SHORT POSITIONS</strong></p>
<div class="lb-trans"><p><strong>2. 利益和空頭頭寸</strong></p>
</div><p><strong>(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)</strong></p>
<div class="lb-trans"><p><strong>(a) 在所交易的相關證券類別中的利益和空頭頭寸（交易後）(注 2)</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Long</td>
<td>Short</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number</td>
<td>(%)</td>
<td>Number</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) Relevant securities</td>
<td>943,558</td>
<td>(0.96)</td>
<td>486,565</td>
<td>(0.49)</td>
</tr>
<tr>
<td>(2) Derivatives (other than options)</td>
<td>39,256</td>
<td>(0.04)</td>
<td>63,843</td>
<td>(0.06)</td>
</tr>
<tr>
<td>(3) Options and agreements to purchase/sell</td>
<td>0</td>
<td>(0.00)</td>
<td>0</td>
<td>(0.00)</td>
</tr>
<tr>
<td>Total</td>
<td>982,814</td>
<td>(1.00)</td>
<td>550,408</td>
<td>(0.56)</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>多頭</td>
<td>空頭</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>數量</td>
<td>(%)</td>
<td>數量</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) 相關證券</td>
<td>943,558</td>
<td>(0.96)</td>
<td>486,565</td>
<td>(0.49)</td>
</tr>
<tr>
<td>(2) 衍生品（非期權）</td>
<td>39,256</td>
<td>(0.04)</td>
<td>63,843</td>
<td>(0.06)</td>
</tr>
<tr>
<td>(3) 購買/出售的期權和協議</td>
<td>0</td>
<td>(0.00)</td>
<td>0</td>
<td>(0.00)</td>
</tr>
<tr>
<td>總計</td>
<td>982,814</td>
<td>(1.00)</td>
<td>550,408</td>
<td>(0.56)</td>
</tr>
</tbody>
</table>
</div><p><strong>(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)</strong></p>
<div class="lb-trans"><p><strong>(b) 在公司相關證券中的利益和空頭頭寸，除了所交易的類別（注 2）</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security:</td>
<td>Long</td>
<td>Short</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number</td>
<td>(%)</td>
<td>Number</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) Relevant securities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) Derivatives (other than options)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) Options and agreements to purchase/sell</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相關證券類別：</td>
<td>多頭</td>
<td>空頭</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>數量</td>
<td>(%)</td>
<td>數量</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) 相關證券</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 衍生品（非期權）</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 購買/出售的期權和協議</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>總計</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>3. DEALINGS (Note 3)</p>
<div class="lb-trans"><p>3. 交易（注 3）</p>
</div><p><strong>(a) Purchases and sales</strong></p>
<div class="lb-trans"><p><strong>(a) 購買和銷售</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Purchase/sale</td>
<td>Number of relevant securities</td>
<td>Price per unit (Note 4)</td>
</tr>
<tr>
<td>Purchase</td>
<td>5,451</td>
<td>21.6050 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>300</td>
<td>21.6150 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>1,162</td>
<td>21.6150 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>400</td>
<td>21.6150 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>1,232</td>
<td>21.6150 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>1,493</td>
<td>21.6150 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>381</td>
<td>21.6250 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>21</td>
<td>21.6350 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>100</td>
<td>21.6350 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>75</td>
<td>21.6350 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>188</td>
<td>21.6350 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>100</td>
<td>21.6350 USD</td>
</tr>
<tr>
<td>Sale (Loan New)</td>
<td>1,300</td>
<td>N/A</td>
</tr>
<tr>
<td>Purchase (Loan Full Return)</td>
<td>1,300</td>
<td>N/A</td>
</tr>
<tr>
<td>Sale (Loan New)</td>
<td>1,300</td>
<td>N/A</td>
</tr>
<tr>
<td>Purchase (Loan Partial Return)</td>
<td>659</td>
<td>N/A</td>
</tr>
<tr>
<td>Sale (Loan New)</td>
<td>690</td>
<td>N/A</td>
</tr>
<tr>
<td>Purchase (Loan Full Return)</td>
<td>690</td>
<td>N/A</td>
</tr>
<tr>
<td>Sale (Borrow Partial Return)</td>
<td>194,400</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>購買/銷售</td>
<td>相關證券數量</td>
<td>每單位價格（注 4）</td>
</tr>
<tr>
<td>購買</td>
<td>5,451</td>
<td>21.6050 美元</td>
</tr>
<tr>
<td>購買</td>
<td>300</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>購買</td>
<td>1,162</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>購買</td>
<td>400</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>購買</td>
<td>1,232</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>購買</td>
<td>1,493</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>購買</td>
<td>381</td>
<td>21.6250 美元</td>
</tr>
<tr>
<td>購買</td>
<td>21</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>購買</td>
<td>100</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>購買</td>
<td>75</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>購買</td>
<td>188</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>購買</td>
<td>100</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>銷售（新貸款）</td>
<td>1,300</td>
<td>不適用</td>
</tr>
<tr>
<td>購買（貸款全額歸還）</td>
<td>1,300</td>
<td>不適用</td>
</tr>
<tr>
<td>銷售（新貸款）</td>
<td>1,300</td>
<td>不適用</td>
</tr>
<tr>
<td>購買（貸款部分歸還）</td>
<td>659</td>
<td>不適用</td>
</tr>
<tr>
<td>銷售（新貸款）</td>
<td>690</td>
<td>不適用</td>
</tr>
<tr>
<td>購買（貸款全額歸還）</td>
<td>690</td>
<td>不適用</td>
</tr>
<tr>
<td>銷售（借入部分歸還）</td>
<td>194,400</td>
<td>不適用</td>
</tr>
</tbody>
</table>
</div><p><strong>(b) Derivatives transactions (other than options transactions)</strong></p>
<div class="lb-trans"><p><strong>(b) 衍生品交易（非期權交易）</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Product name, e.g. CFD</td>
<td>CFD</td>
</tr>
<tr>
<td>Nature of transaction (Note 5)</td>
<td>Reducing a long position</td>
</tr>
<tr>
<td>Number of relevant securities (Note 6)</td>
<td>10,903</td>
</tr>
<tr>
<td>Price per unit (Note 4)</td>
<td>21.5893 USD</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>產品名稱，例如 CFD</td>
<td>CFD</td>
</tr>
<tr>
<td>交易性質（注 5）</td>
<td>減少多頭頭寸</td>
</tr>
<tr>
<td>相關證券數量（注 6）</td>
<td>10,903</td>
</tr>
<tr>
<td>每單位價格（注 4）</td>
<td>21.5893 美元</td>
</tr>
</tbody>
</table>
</div><p><strong>(c) Options transactions in respect of existing relevant securities</strong></p>
<div class="lb-trans"><p><strong>(c) 關於現有相關證券的期權交易</strong></p>
</div><p><strong>(i) Writing, selling, purchasing or varying</strong></p>
<div class="lb-trans"><p><strong>(i) 寫入、出售、購買或變更</strong></p>
</div><ul>
<li>Product name,e.g. call option</li>
<li>Writing, selling, purchasing, varying etc.</li>
<li>Number of securities to which the option relates (Note 7)</li>
<li>Exercise price</li>
<li>Type, e.g. American, European etc.</li>
<li>Expiry date</li>
<li>Option money paid/received per unit (Note 4)</li>
</ul>
<div class="lb-trans"><ul>
<li>產品名稱，例如看漲期權</li>
<li>寫入、出售、購買、變更等</li>
<li>與期權相關的證券數量（注 7）</li>
<li>行使價格</li>
<li>類型，例如美式、歐式等</li>
<li>到期日期</li>
<li>每單位支付/收到的期權費用（注 4）</li>
</ul>
</div><p><strong>(ii) Exercising</strong></p>
<div class="lb-trans"><p><strong>(ii) 行使</strong></p>
</div><ul>
<li>Product name,e.g. call option</li>
<li>Number of securities</li>
<li>Exercise price per unit (Note 4)</li>
</ul>
<div class="lb-trans"><ul>
<li>產品名稱，例如看漲期權</li>
<li>證券數量</li>
<li>每單位行使價格（注 4）</li>
</ul>
</div><p><strong>(d) Other dealings (including transactions in respect of new securities) (Note 3)</strong></p>
<div class="lb-trans"><p><strong>(d) 其他交易（包括新證券的交易）（注 3）</strong></p>
</div><ul>
<li>Nature of transaction (Note 7)</li>
<li>Details</li>
<li>Price per unit (if applicable) (Note 4)</li>
</ul>
<div class="lb-trans"><ul>
<li>交易性質（注 7）</li>
<li>詳情</li>
<li>每單位價格（如適用）（注 4）</li>
</ul>
</div><p><strong>4. OTHER INFORMATION</strong></p>
<div class="lb-trans"><p><strong>4. 其他信息</strong></p>
</div><p><strong>Agreements, arrangements or understandings relating to options or derivatives</strong></p>
<div class="lb-trans"><p><strong>與期權或衍生品相關的協議、安排或理解</strong></p>
</div><ul>
<li>Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.</li>
<li>NONE</li>
</ul>
<div class="lb-trans"><ul>
<li>任何披露人和其他人之間關於本表格中提到的任何期權下相關證券投票權的協議、安排或理解的完整細節，或關於本表格中提到的任何衍生品的相關證券的投票權或未來收購或處置的協議。如果沒有，應予以説明。</li>
<li>無</li>
</ul>
</div><p>Is a Supplemental Form 8 attached? (Note 9) YES</p>
<div class="lb-trans"><p>是否附有補充表格 8？（注 9）是</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure</td>
<td>24 December 2025</td>
</tr>
<tr>
<td>Contact name</td>
<td>Papa Lette and Andrzej Szyszka</td>
</tr>
<tr>
<td>Telephone number</td>
<td>+33(1) 4212 1459 / +48(22) 317 4817</td>
</tr>
<tr>
<td>Name of offeree/offeror with which connected</td>
<td>AVADEL PHARMACEUTICALS PLC</td>
</tr>
<tr>
<td>Nature of connection (Note 9)</td>
<td>Advisor to Offeree</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 12 月 24 日</td>
</tr>
<tr>
<td>聯繫人姓名</td>
<td>Papa Lette 和 Andrzej Szyszka</td>
</tr>
<tr>
<td>電話號碼</td>
<td>+33(1) 4212 1459 / +48(22) 317 4817</td>
</tr>
<tr>
<td>與之相關的受要約方/要約方名稱</td>
<td>Avadel Pharmaceuticals PLC</td>
</tr>
<tr>
<td>關係性質（注 9）</td>
<td>受要約方顧問</td>
</tr>
</tbody>
</table>
</div><p><strong>SUPPLEMENTAL FORM 38.5(b)</strong></p>
<div class="lb-trans"><p><strong>補充表格 38.5(b)</strong></p>
</div><p><strong>IRISH TAKEOVER PANEL</strong></p>
<div class="lb-trans"><p><strong>愛爾蘭收購委員會</strong></p>
</div><p><strong>DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013</strong></p>
<div class="lb-trans"><p><strong>根據 1997 年愛爾蘭收購委員會法第 38.5(b) 條款的披露，收購規則，2013</strong></p>
</div><p><strong>DETAILS OF OPEN POSITIONS</strong></p>
<div class="lb-trans"><p><strong>開放頭寸的詳細信息</strong></p>
</div><p><strong>OPEN POSITIONS (Note 1)</strong></p>
<div class="lb-trans"><p><strong>開放頭寸（注 1）</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Product name,e.g. call option</td>
<td>Written or purchased</td>
<td>Number of relevant securities to which the option or derivative relates</td>
<td>Exercise price (Note 2)</td>
<td>Type, e.g. American, European etc.</td>
<td>Expiry date</td>
</tr>
<tr>
<td>Swap</td>
<td>Sold</td>
<td>84</td>
<td>0.0000</td>
<td>N/A</td>
<td>13/03/2026</td>
</tr>
<tr>
<td>Swap</td>
<td>Purchased</td>
<td>33,762</td>
<td>0.0000</td>
<td>N/A</td>
<td>20/01/2026</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>產品名稱，例如看漲期權</td>
<td>寫入或購買</td>
<td>與期權或衍生品相關的相關證券數量</td>
<td>行使價格（注 2）</td>
<td>類型，例如美式、歐式等</td>
<td>到期日期</td>
</tr>
<tr>
<td>互換</td>
<td>出售</td>
<td>84</td>
<td>0.0000</td>
<td>不適用</td>
<td>2026 年 3 月 13 日</td>
</tr>
<tr>
<td>互換</td>
<td>購買</td>
<td>33,762</td>
<td>0.0000</td>
<td>不適用</td>
<td>2026 年 1 月 20 日</td>
</tr>
</tbody>
</table>
</div><p>Notes</p>
<div class="lb-trans"><p>註釋</p>
</div><p>1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.</p>
<div class="lb-trans"><p>1. 如果存在開放的期權頭寸或開放的衍生品頭寸（除 CFD 外），應提供完整的細節。任何現有的購買或出售協議的完整細節也必須在本表格中提供。</p>
</div><p>2. For all prices and other monetary amounts, the currency must be stated.</p>
<div class="lb-trans"><p>2. 所有價格和其他貨幣金額必須註明貨幣。</p>
</div><p>For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.</p>
<div class="lb-trans"><p>有關披露要求的完整細節，請參見規則 8 和規則 38.5。如果有疑問，請諮詢委員會。</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，倫敦證券交易所的新聞服務。RNS 已獲得金融行為監管局的批准，作為英國的主要信息提供者。有關使用和分發此信息的條款和條件可能適用。如需更多信息，請聯繫 rns@lseg.com 或訪問 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPUSVARVOUUUAA</p>
<div class="lb-trans"><p>RNS 可能會使用您的 IP 地址來確認您是否遵守條款和條件，分析您與本次溝通中所包含信息的互動方式，並將此分析以匿名方式與他人分享，作為我們商業服務的一部分。有關 RNS 和倫敦證券交易所如何使用您提供的個人數據的更多信息，請參閲我們的隱私政策。END ITPUSVARVOUUUAA</p>
</div>

REG - 高盛 & Co. Avadel 製藥公司 - 38.5b-Avadel 製藥公司